These findings have led to the development of several BRAF and MEK inhibitors (BRAFi and MEKi, respectively) that have received approval by the US Food and Drug Administration (FDA) for use in the treatment of unresectable metastatic melanoma (8–10). The gene discussed is BRAF; the disease is metastatic melanoma.